SEC Form 4 · accession 0000899243-17-019840
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara K Finck
Officer — Chief Medical Officer
Period of report
Aug 6, 2017
Accepted (ET)
Aug 8, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | holding | — | — | — | 26,791 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.70 | Aug 6, 2017 | A | 67,000 | A | — | Aug 6, 2027 | Common Stock | 67,000 | 67,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to (i) fifty percent (50%) of the total number of shares subject to the option after one year measured from August 1, 2017 (the "Vesting Commencement Date"), (ii) an additional twenty-five percent (25%) of the total number of shares subject to the option on the eighteen (18) month anniversary of the Vesting Commencement Date and (iii) an additional twenty-five percent (25%) of the total number of shares subject to the option on the two year anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.